PaxMedica Overview
Latest ROE for PaxMedica: 977.01% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow977.01%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for PXMD is 977.01%. That is above the sector sector average of -5.68%. Investors often review this figure alongside PaxMedica's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, PXMD currently prints 977.01% for ROE, while the sector average sits near -5.68%. That is roughly 17293.4% above the sector mean. Large gaps often invite a closer look at PaxMedica's growth, margins, and balance sheet.
Return on Equity shows how effectively PaxMedica converts resources into returns. At 977.01%, PXMD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PXMD's ROE (977.01%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
